Previous studies have demonstrated that radiomics can distinguish tumors with EGFR mutations from those with wild-type EGFR (16, 17) and provides a noninvasive and quantified approach to gain insight into tumor heterogeneity. This evidence concerns the gene EGFR and neoplasm.